Substituted isoindoles and the use thereof
View Patent ↗The invention relates to the field of blood clotting, to novel compounds of formula (I), to a method for their production and to the use of these compounds as active ingredients in medicaments for preventing and/or treating diseases. The compounds are factor Xa inhibitors.
1. A compound of the formula (I)
in which
R 1 and R 2 together represent O and
R 3 and R 4 together represent O, or
R 1 represents hydrogen, hydroxy or (C 1 -C 4 )-alkoxy,
R 2 represents hydrogen and
R 3 and R 4 together represent O, or
R 1 and R 2 together represent O,
R 3 represents hydrogen, hydroxy or (C 1 -C 4 )-alkoxy and
R 4 represents hydrogen,
R 5 and R 6 represent hydrogen and
R 7 and R 8 together represent
in which
R 9 represents halogen, trifluoromethyl or methyl, or
R 5 , R 6 , R 7 and R 8 together represent
in which
R 9 is as defined above,
A represents (C 1 -C 4 )-alkanediyl or (C 2 -C 4 )-alkenediyl,
B represents phenylene or cyclohexanediyl, which radicals may be substituted by amino, urea, sulfamoyl, —C(═N—NH—C(═NH)—NH 2 )—H, or —C(═NR 10 )—R 11 ,
in which
R 10 represents hydrogen or —NH—C(═NH)—NH 2 ,
R 11 represents —NR 12 R 13 or 5- to 10-membered heterocyclyl,
in which
R 12 and R 13 , independently of one another, represent hydrogen, (C 1 -C 4 )-alkyl or (C 3 -C 7 )-cycloalkyl,
(C 1 -C 4 )-alkyl, which for its part may be substituted by cyano, (C 1 -C 4 )-alkoxycarbonyl, optionally (C 1 -C 4 )-alkyl-substituted 5- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, tri-(C 1 -C 4 )-alkylammonium, —NR 14 R 15 , —C(═NR 16 )—R 17 , —N—C(═O)—R 18 or —N—C(═O)—NH—R 19 ,
in which
R 14 represents hydrogen, mono- or di-(C 1 -C 4 )-alkylamino, (C 1 -C 4 )-alkyl which is optionally substituted by 5- to 10-membered heteroaryl, represents 5- to 10-membered heterocyclyl, (C 6 -C 10 )-aryl or 5- to 10-membered heteroaryl, where the rings for their part may be substituted by halogen,
R 15 represents hydrogen or optionally cyano-substituted (C 1 -C 4 )-alkyl,
R 16 represents hydrogen or hydroxy,
R 17 represents amino, 5- to 10-membered heterocyclyl, optionally amino- or trifluoromethyl-substituted mono- or di-(C 1 -C 4 )-alkylamino, optionally trifluoromethyl-substituted (C 3 -C 7 )-cycloalkylamino,
R 18 represents trifluoromethyl, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy or 5- to 10-membered heterocyclyl which is optionally substituted by (C 1 -C 4 )-alkyl,
R 19 represents hydrogen, amino, dimethylamino, 5- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, or represents (C 1 -C 4 )-alkyl which is optionally substituted by (C 1 -C 4 )-alkoxycarbonyl, dimethylamino, carbamoyl or 5- to 10-membered heteroaryl,
(C 1 -C 4 )-alkoxy, which for its part may be mono- or disubstituted, independently of one another, by cyano, thiocarbamoyl, optionally (C 1 -C 4 )-alkyl-substituted 5- to 10-membered heterocyclyl, optionally halogen-substituted 5- to 10-membered heteroaryl, optionally —C(═NR 20 )—R 21 -substituted (C 6 -C 10 )-aryl or —C(═NR 20 )—R 21 ,
in which
R 20 represents hydrogen, hydroxy, (C 3 -C 7 )-cycloalkyl or optionally hydroxy-substituted (C 1 -C 4 )-alkyl,
R 21 represents amino, (C 1 -C 4 )-alkylthio, (C 3 -C 7 )-cycloalkylamino, benzylamino or 5- to 10-membered heterocyclyl,
5- to 10-membered heterocyclyl which for its part may be substituted by (C 1 -C 4 )-alkyl,
(C 6 -C 10 )-aryl which for its part may be mono- or disubstituted, independently of one another, by halogen, cyano, carbamoyl or optionally amino-substituted (C 1 -C 4 )-alkyl,
5- to 10-membered heteroaryloxy which for its part may be substituted by amino or N—(C 1 -C 4 )-alkylaminocarbonyl,
or 5- to 10-membered heteroaryl which for its part may be substituted by amino,
or a salt hydrate, hydrate of the salt, or solvate thereof.
2. The compound as claimed in claim 1
in which
R 1 and R 2 together represent O and
R 3 and R 4 together represent O, or
R 1 represents hydrogen, hydroxy, methoxy or ethoxy,
R 2 represents hydrogen and
R 3 and R 4 together represent O, or
R 1 and R 2 together represent O,
R 3 represents hydrogen, hydroxy, methoxy or ethoxy and
R 4 represents hydrogen,
R 5 and R 6 represent hydrogen and
R 7 and R 8 together represent
in which
R 9 represents halogen or trifluoromethyl, or
R 5 , R 6 , R 7 and R 8 together represent
in which
R 9 is as defined above,
A represents (C 1 -C 3 )-alkanediyl or (C 2 -C 3 )-alkenediyl,
B represents phenylene or cyclohexanediyl, which radicals may be substituted by —C(═NR 10 )—R 11
in which
R 10 represents hydrogen,
R 11 represents —NR 12 R 13 or 5- to 10-membered heterocyclyl,
in which
R 12 and R 13 , independently of one another, represent hydrogen, (C 1 -C 4 )-alkyl or (C 3 -C 7 )-cycloalkyl,
methyl or ethyl which for their part may be substitued by cyano, methoxycarbonyl, optionally methyl- or ethyl-substituted 5- or 6-membered heterocyclyl, 5- or 6-membered heteroaryl, tri-(C 1 -C 2 )-alkylammonium, —NR 14 R 15 , —C(═NR 16 )—R 17 , —N—C(═O)—R 18 or —N—C(═O)—NH—R 19 ,
in which
R 14 represents hydrogen, dimethylamino, methyl or ethyl, which radicals are optionally substituted by 5- or 6-membered heteroaryl, represents 5- or 6-membered heterocyclyl or 5- or 6-membered heteroaryl, which may be substituted by halogen,
R 15 represents hydrogen, methyl or ethyl,
R 16 represents hydrogen,
R 17 represents amino, 5- or 6-membered heterocyclyl, optionally amino- or trifluoromethyl-substituted mono- or di-(C 1 -C 4 )-alkylamino, optionally trifluoromethyl-substituted (C 3 -C 7 )-cycloalkylamino,
R 18 represents trifluoromethyl or (C 1 -C 4 )-alkyl,
R 19 represents hydrogen, amino or optionally methoxy- or ethoxycarbonyl-substituted (C 1 -C 4 )-alkyl,
methoxy or ethoxy which for their part may be mono- or disubstituted, independently of one another, by optionally methyl-substituted 5- or 6-membered heterocyclyl or —C(═NR 20 )—R 21 ,
in which
R 20 represents hydrogen,
R 21 represents amino, (C 3 -C 6 )-cycloalkylamino, benzylamino or 5- or 6-membered heterocyclyl, or pyridyl,
or a salt, hydrate, hydrate of the salt, or solvate thereof.
3. The compound as claimed in claim 1
in which
R 1 and R 2 together represent O and
R 3 and R 4 together represent O, or
R 1 represents hydrogen, hydroxy or methoxy,
R 2 represents hydrogen and
R 3 and R 4 together represent O, or
R 1 and R 2 together represent O,
R 3 represents hydrogen, hydroxy or methoxy and
R 4 represents hydrogen,
R 5 and R 6 represent hydrogen and
R 7 and R 8 together represent
in which
R 9 represents chlorine or bromine, or
R 5 , R 6 , R 7 and R 8 together represent
in which
R 9 is as defined above,
A represents methanediyl or ethanediyl,
B represents phenylene which may be substituted by —C(═NR 10 )—R 11
in which
R 10 represents hydrogen,
R 11 represents amino,
methyl which for its part may be substituted by cyano, optionally methyl-substituted imidazolinyl or tetrahydropyrimidinyl, —NR 14 R 15 or —C(═NR 16 )—R 17 ,
in which
R 14 represents optionally pyridyl-substituted methyl or pyridyl,
R 15 represents hydrogen,
R 16 represents hydrogen,
R 17 represents amino, piperidinyl, morpholinyl, pyrrolidinyl, optionally amino- or trifluoromethyl-substituted mono- or di-(C 1 -C 3 )-alkylamino or optionally trifluoromethyl-substituted cyclopropyl-, cyclopentyl- or cyclohexylamino,
or methoxy or ethoxy which for their part may be substituted by —C(═NH)—NH 2 ,
or a salt, hydrate, hydrate of the salt, or solvate thereof.
4. A process for preparing compounds of the formula (1) as defined in claim 1 , characterized in that
either
(A) a compound of the formula (IV)
in which R 5 , R 6 , R 7 and R 8 are as defined in claim 1
is reacted with a compound of the formula (V)
Y-A-B
in which A and B are as defined in claim 1 and Y represents a suitable leaving group
to give a compound of the formula (I)
in which both R 1 and R 2 and R 3 and R 4 , in each case together, represent O and R 5 , R 6 , R 7 , R 8 , A and B are as defined in claim 1 , or
(B1) a compound of the formula (VIII) or (VIIIa)
in which A and B are as defined in claim 1
is reacted with a compound of the formula (III)
in which R 9 is as defined in claim 1 and X represents a leaving group
to give a compound of the formula (I)
in which both R 1 and R 2 and R 3 and R 4 , in each case together, represent O and R 5 , R 6 , R 7 , R 8 , A and B are as defined in claim 1 , or
(B2) a compound of the formula (IX)
in which A and B are as defined in claim 1
or a compound of the formula (X)
in which A and B are as defined in claim 1
is reacted with a compounds a compound of the formula (III) to give a compound of the formula (I)
in which R 1 and R 2 together represent O, R 3 represents hydrogen or hydroxy, R 4 represents hydrogen or R 3 and R 4 together represent O, R 1 represents hydrogen or hydroxy, R 2 represents hydrogen and R 5 , R 6 , R 7 , R 8 , A and B are as defined in claim 1 , or
(C) a compound of the formula (XIV)
in which A and B are as defined in claim 1
is reacted with a compound of the formula (III) to give a compound of the formula (I)
in which R 1 and R 2 represent hydrogen, R 3 and R 4 together represent O and R 5 , R 6 , R 7 , R 8 , A and B are as defined in claim 1 ,
where the resulting compound of the formula (I) may, if appropriate, subsequently be subjected to further derivatization which can be carried out by customary methods.
5. A pharmaceutical composition, comprising at least one compound of the formula (I) as defined in claim 1 and at least one further auxiliary.
6. A pharmaceutical composition, comprising at least one compound of the formula (I) as defined in claim 1 and at least one further active compound.
7. A method for the treatment of thromboembolic disorders, comprising administering an effective amount of a compound of claim 1 .
8. A method for treatment of disseminated intravascular coagulation (DIC) comprising administering an effective amount of a compound of claim 1 .
9. A method for treatment of atherosclerosis, arthritis, or Alzheimer's disease comprising administering an effective amount of a compound of claim 1 .
10. A method for preventing the coagulation of blood in vitro, characterized in that a compound of the formula (I) as defined in claim 1 is added.
11. The method of claim 7 wherein said thromboembolic disorder is myocardial infarction, angina pectoris, reocclusion and restenosis after angioplasty or aortocoronary bypass, stroke, transitory ischemic attack, peripheral arterial occlusive disease, pulmonary embolism or deep venous thrombosis.
12. The method of claim 11 wherein said angina pectoris is unstable angina.
13. The method of claim 10 , wherein said blood is banked blood or a biological sample containing factor Xa.